These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33951528)

  • 1. More Effective Anticoagulation During Non-Cardiac Arterial Procedures Using Activated Clotting Time Guided Heparin Administration.
    Doganer O; Wiersema AM; Pierie M; Blankensteijn JD; Yeung KK; Jongkind V
    Ann Vasc Surg; 2021 Oct; 76():378-388. PubMed ID: 33951528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Standardized Bolus of 5 000 IU of Heparin Does not Lead to Adequate Heparinization during Non-cardiac Arterial Procedures.
    Doganer O; Jongkind V; Blankensteijn JD; Yeung KK; Wiersema AM
    Ann Vasc Surg; 2021 Feb; 71():280-287. PubMed ID: 32768536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No Concluding Evidence on Optimal Activated Clotting Time for Non-cardiac Arterial Procedures.
    Doganer O; Wiersema AM; Scholtes V; Blankensteijn JD; Yeung KK; Jongkind V
    Eur J Vasc Endovasc Surg; 2020 Jan; 59(1):137-147. PubMed ID: 31699657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant Effect of Standard Dose Heparin During Peripheral Endovascular Intervention.
    Nissborg E; Wahlgren CM
    Ann Vasc Surg; 2019 Oct; 60():286-292. PubMed ID: 31075466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
    Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
    J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight Based Heparin Dosage with Activated Clotting Time Monitoring Leads to Adequate and Safe Anticoagulation in Non-Cardiac Arterial Procedures.
    Doganer O; Roosendaal LC; Wiersema AM; Blankensteijn JD; Yeung KK; Jongkind V
    Ann Vasc Surg; 2022 Aug; 84():327-335. PubMed ID: 35248743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Additional Value of Activated Clotting Time-Guided Heparinization During Interventions for Peripheral Arterial Disease.
    Roosendaal LC; Radović M; Hoebink M; Wiersema AM; Blankensteijn JD; Jongkind V
    J Endovasc Ther; 2023 Nov; ():15266028231213611. PubMed ID: 38008930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACTION-1: study protocol for a randomised controlled trial on ACT-guided heparinization during open abdominal aortic aneurysm repair.
    Wiersema AM; Roosendaal LC; Koelemaij MJW; Tijssen JGP; van Dieren S; Blankensteijn JD; Debus ES; Middeldorp S; Heyligers JMM; Fokma YS; Reijnen MMPJ; Jongkind V
    Trials; 2021 Sep; 22(1):639. PubMed ID: 34538275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of baseline activated clotting time-guided heparin administration in reducing bleeding events during transfemoral transcatheter aortic valve implantation.
    Bernelli C; Chieffo A; Montorfano M; Maisano F; Giustino G; Buchanan GL; Chan J; Costopoulos C; Latib A; Figini F; De Meo E; Giannini F; Covello RD; Gerli C; Franco A; Agricola E; Spagnolo P; Cioni M; Alfieri O; Camici PG; Colombo A
    JACC Cardiovasc Interv; 2014 Feb; 7(2):140-151. PubMed ID: 24556092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is 300 Seconds ACT Safe and Efficient during MiECC Procedures?
    Bauer A; Hausmann H; Schaarschmidt J; Szlapka M; Scharpenberg M; Eberle T; Hasenkam JM
    Thorac Cardiovasc Surg; 2019 Apr; 67(3):191-202. PubMed ID: 29290078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial.
    Dillinger JG; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Nicolau JC; Henry P; Kedev S; Wiviott SD; Sabatine MS; Mehta SR; Steg PG
    Circ Cardiovasc Interv; 2018 Jun; 11(6):e006084. PubMed ID: 29895599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment.
    Zhang RF; Ma CM; Wang N; Yang MH; Li WW; Yin XM; Dong YX; Yu XH; Xiao XJ; Xia YL; Gao LJ
    BMC Cardiovasc Disord; 2021 Apr; 21(1):214. PubMed ID: 33906609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated clotting time-guided heparinization during open AAA surgery: a pilot study.
    Roosendaal LC; Hoebink M; Wiersema AM; Blankensteijn JD; Jongkind V
    Pilot Feasibility Stud; 2024 May; 10(1):73. PubMed ID: 38720378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Smoking on the Activated Clotting Time and the Incidence of Complications in Noncardiac Arterial Procedures.
    Roosendaal LC; van Os TEK; van Es N; Hoebink M; Wiersema AM; Blankensteijn JD; Jongkind V
    J Endovasc Ther; 2023 Oct; ():15266028231207027. PubMed ID: 37887702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of the concomitant use of heparin on the effects of warfarin during catheter ablation for atrial fibrillation.
    Inada K; Matsuo S; Tokutake K; Yokoyama K; Hioki M; Narui R; Ito K; Tanigawa S; Yamashita S; Tokuda M; Shibayama K; Miyanaga S; Sugimoto K; Yoshimura M; Yamane T
    Heart Vessels; 2016 Mar; 31(3):397-401. PubMed ID: 25471944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
    J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of fixed-dose heparin in carotid endarterectomy.
    Poisik A; Heyer EJ; Solomon RA; Quest DO; Adams DC; Baldasserini CM; McMahon DJ; Huang J; Kim LJ; Choudhri TF; Connolly ES
    Neurosurgery; 1999 Sep; 45(3):434-41; discussion 441-2. PubMed ID: 10493364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Influencing ACT After Intravenous Bolus Administration of 100 IU/kg of Unfractionated Heparin During Cardiac Catheterization in Children.
    Muster I; Haas T; Quandt D; Kretschmar O; Knirsch W
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):740-747. PubMed ID: 27514640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perprocedural Heparinization in Non-cardiac Arterial Procedures: The Current Practice in the Netherlands.
    Roosendaal LC; Hoebink M; Wiersema AM; Yeung KK; Blankensteijn JD; Jongkind V;
    J Endovasc Ther; 2023 Sep; ():15266028231199714. PubMed ID: 37746826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How much heparin do we really need to go on pump? A rethink of current practices.
    Shuhaibar MN; Hargrove M; Millat MH; O'Donnell A; Aherne T
    Eur J Cardiothorac Surg; 2004 Nov; 26(5):947-50. PubMed ID: 15519187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.